184 related articles for article (PubMed ID: 30933045)
1. Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy.
Bera TK; Liu W; Leshem J; King E; Kozlov S; Pastan I
J Immunother; 2019 May; 42(4):119-125. PubMed ID: 30933045
[TBL] [Abstract][Full Text] [Related]
2. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
[TBL] [Abstract][Full Text] [Related]
3. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A; Bera TK; Liu X; Wei J; Pastan I
Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
[TBL] [Abstract][Full Text] [Related]
4. Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Leshem Y; O'Brien J; Liu X; Bera TK; Terabe M; Berzofsky JA; Bossenmaier B; Niederfellner G; Tai CH; Reiter Y; Pastan I
Cancer Immunol Res; 2017 Aug; 5(8):685-694. PubMed ID: 28674083
[TBL] [Abstract][Full Text] [Related]
5. Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries.
Hsu HJ; Tung CP; Yu CM; Chen CY; Chen HS; Huang YC; Tsai PH; Lin SI; Peng HP; Chiu YK; Tsou YL; Kuo WY; Jian JW; Hung FH; Hsieh CY; Hsiao M; Chuang SS; Shen CN; Wang YA; Yang AS
Sci Rep; 2021 Jul; 11(1):15430. PubMed ID: 34326410
[TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.
Lejeune P; Cruciani V; Berg-Larsen A; Schlicker A; Mobergslien A; Bartnitzky L; Berndt S; Zitzmann-Kolbe S; Kamfenkel C; Stargard S; Hammer S; Jørgensen JS; Jackerott M; Nielsen CH; Schatz CA; Hennekes H; Karlsson J; Cuthbertson AS; Mumberg D; Hagemann UB
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615703
[TBL] [Abstract][Full Text] [Related]
7. Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures.
Liu W; Tai CH; Liu X; Pastan I
Proc Natl Acad Sci U S A; 2022 Nov; 119(48):e2214928119. PubMed ID: 36409889
[TBL] [Abstract][Full Text] [Related]
8. Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell.
Jafarzadeh L; Masoumi E; Alishah K; Mirzaei HR; Jamali A; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):264-275. PubMed ID: 32615660
[TBL] [Abstract][Full Text] [Related]
9. Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes.
Kolyvas E; Rudloff M; Poruchynsky M; Landsman R; Hollevoet K; Venzon D; Alewine C
Oncotarget; 2017 Feb; 8(6):9189-9199. PubMed ID: 27999204
[TBL] [Abstract][Full Text] [Related]
10. An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin.
Snell D; Gunde T; Warmuth S; Chatterjee B; Brock M; Hess C; Johansson M; Simonin A; Spiga FM; Weinert C; Kirk N; Bassler N; Campos Carrascosa L; Flückiger N; Heiz R; Wagen S; Giezendanner N; Alberti A; Yaman Y; Mahler D; Diem D; Lichtlen P; Urech D
Oncoimmunology; 2023; 12(1):2233401. PubMed ID: 37456982
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a novel anti-mesothelin immunotoxin based on a single domain antibody as the targeting ligand.
Li Q; Li W; Xu K; Xing Y; Ding Y; Jing Z; Wang X; Hong Z
Int J Pharm; 2021 Jun; 602():120647. PubMed ID: 33915185
[TBL] [Abstract][Full Text] [Related]
12. Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.
Hatterer E; Chauchet X; Richard F; Barba L; Moine V; Chatel L; Broyer L; Pontini G; Bautzova T; Juan F; Calloud S; Bosson N; Charreton M; Masternak K; Buatois V; Shang L
MAbs; 2020; 12(1):1739408. PubMed ID: 32191151
[TBL] [Abstract][Full Text] [Related]
13. Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers.
Hagerty B; O'Sullivan TN; Zhang X; Collins NK; Custer Lawrence W; Bassel LL; Pate N; Xu J; Guerin TM; Kozlov S; Alewine C
Mol Cancer Ther; 2021 Oct; 20(10):2082-2092. PubMed ID: 34315768
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
Zhu Y; Zuo D; Wang K; Lan S; He H; Chen L; Chen X; Feng M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15027-15038. PubMed ID: 37612388
[TBL] [Abstract][Full Text] [Related]
15. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
[TBL] [Abstract][Full Text] [Related]
16. Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation.
Chen YL; Chang MC; Chiang YC; Lin HW; Sun NY; Chen CA; Sun WZ; Cheng WF
Cancer Lett; 2018 Jul; 425():152-163. PubMed ID: 29596890
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.
Alewine C; Xiang L; Yamori T; Niederfellner G; Bosslet K; Pastan I
Mol Cancer Ther; 2014 Nov; 13(11):2653-61. PubMed ID: 25239937
[TBL] [Abstract][Full Text] [Related]
18. Generation of a Novel Mesothelin-Targeted Oncolytic
Froechlich G; Gentile C; Infante L; Caiazza C; Pagano P; Scatigna S; Cotugno G; D'Alise AM; Lahm A; Scarselli E; Nicosia A; Mallardo M; Sasso E; Zambrano N
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33418877
[TBL] [Abstract][Full Text] [Related]
19. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.
Chowdhury PS; Viner JL; Beers R; Pastan I
Proc Natl Acad Sci U S A; 1998 Jan; 95(2):669-74. PubMed ID: 9435250
[TBL] [Abstract][Full Text] [Related]
20. A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
Ye S; Cohen D; Belmar NA; Choi D; Tan SS; Sho M; Akamatsu Y; Kim H; Iyer R; Cabel J; Lake M; Song D; Harlan J; Zhang C; Fang Y; Wahl AF; Culp P; Hollenbaugh D; Chao DT
Cancer Immunol Res; 2019 Nov; 7(11):1864-1875. PubMed ID: 31462409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]